{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urologic+Neoplasms&page=5", "query": { "condition": "Urologic Neoplasms", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 2409, "total_pages": 241, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urologic+Neoplasms&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urologic+Neoplasms&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T12:11:55.169Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04398368", "title": "Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage 0a Renal Pelvis and Ureter Cancer AJCC v8", "Stage 0a Renal Pelvis Cancer AJCC v8", "Stage 0a Ureter Cancer AJCC v8", "Stage 0is Renal Pelvis and Ureter Cancer AJCC v8", "Stage 0is Renal Pelvis Cancer AJCC v8", "Stage 0is Ureter Cancer AJCC v8", "Stage I Renal Pelvis and Ureter Cancer AJCC v8", "Stage I Renal Pelvis Cancer AJCC v8", "Stage I Ureter Cancer AJCC v8", "Stage II Renal Pelvis and Ureter Cancer AJCC v8", "Stage II Renal Pelvis Cancer AJCC v8", "Stage II Ureter Cancer AJCC v8", "Stage III Renal Pelvis and Ureter Cancer AJCC v8", "Stage III Renal Pelvis Cancer AJCC v8", "Stage III Ureter Cancer AJCC v8", "Stage IV Renal Pelvis and Ureter Cancer AJCC v8", "Stage IV Renal Pelvis Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8" ], "interventions": [ { "name": "Gemcitabine Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2020-06-05", "completion_date": "2023-02-02", "has_results": true, "last_update_posted_date": "2023-08-08", "last_synced_at": "2026-10-02T12:11:55.169Z", "location_count": 4, "location_summary": "Jacksonville, Florida • Rochester, Minnesota • Winston-Salem, North Carolina + 1 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04398368" }, { "nct_id": "NCT07106762", "title": "Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Urothelial Cancer" ], "interventions": [ { "name": "Iza-bren", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 470, "start_date": "2025-09-30", "completion_date": "2033-11-18", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-02T12:11:55.169Z", "location_count": 35, "location_summary": "Gilbert, Arizona • Fullerton, California • Palo Alto, California + 26 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07106762" }, { "nct_id": "NCT03905889", "title": "A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma Metastatic" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2019-06-05", "completion_date": "2022-03-08", "has_results": false, "last_update_posted_date": "2024-06-25", "last_synced_at": "2026-10-02T12:11:55.169Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT03905889" }, { "nct_id": "NCT02608268", "title": "Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignancies" ], "interventions": [ { "name": "MBG453", "type": "DRUG" }, { "name": "PDR001", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2015-11-23", "completion_date": "2022-08-30", "has_results": true, "last_update_posted_date": "2023-12-06", "last_synced_at": "2026-10-02T12:11:55.169Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Houston, Texas + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02608268" }, { "nct_id": "NCT03055013", "title": "Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Renal Cell Carcinoma", "Sarcomatoid Renal Cell Carcinoma", "Stage II Renal Cell Cancer AJCC v7", "Stage III Renal Cell Cancer AJCC v7", "Unclassified Renal Cell Carcinoma" ], "interventions": [ { "name": "Nephrectomy", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Patient Observation", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 819, "start_date": "2017-04-28", "completion_date": "2031-06-09", "has_results": true, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-02T12:11:55.169Z", "location_count": 396, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 293 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03055013" }, { "nct_id": "NCT02111850", "title": "T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cervical Cancer", "Renal Cancer", "Urothelial Cancer", "Melanoma", "Breast Cancer" ], "interventions": [ { "name": "Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 21, "start_date": "2014-02-07", "completion_date": "2021-03-24", "has_results": true, "last_update_posted_date": "2022-03-29", "last_synced_at": "2026-10-02T12:11:55.169Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02111850" }, { "nct_id": "NCT03672240", "title": "Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Muscle Invasive Bladder Cancer (NMIBC)" ], "interventions": [ { "name": "APL-1202", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Asieris Pharmaceutical Technologies Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 6, "start_date": "2018-11-30", "completion_date": "2020-06-30", "has_results": false, "last_update_posted_date": "2020-07-20", "last_synced_at": "2026-10-02T12:11:55.169Z", "location_count": 2, "location_summary": "New York, New York • Myrtle Beach, South Carolina", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Myrtle Beach", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03672240" }, { "nct_id": "NCT03526250", "title": "Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Recurrent Childhood Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Glioma", "Recurrent Hepatoblastoma", "Recurrent Kidney Wilms Tumor", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Glioma", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Rhabdoid Tumor", "Recurrent Rhabdomyosarcoma", "Recurrent Soft Tissue Sarcoma", "Refractory Ependymoma", "Refractory Ewing Sarcoma", "Refractory Glioma", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Glioma", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Rhabdoid Tumor", "Refractory Rhabdomyosarcoma", "Refractory Soft Tissue Sarcoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 23, "start_date": "2018-08-13", "completion_date": "2024-09-30", "has_results": true, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-10-02T12:11:55.169Z", "location_count": 115, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 93 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03526250" }, { "nct_id": "NCT04669860", "title": "Evaluating the Bacterial and Fungal Microbiome in Patients With Calcium Oxalate Urolithiasis and Renal Cell Carcinoma", "overall_status": "SUSPENDED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Calcium Oxalate Urolithiasis", "Renal Cell Carcinoma" ], "interventions": [], "intervention_types": [], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2021-02-24", "completion_date": "2029-01-01", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-02T12:11:55.169Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04669860" }, { "nct_id": "NCT00118040", "title": "Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Bladder Carcinoma", "Stage I Bladder Cancer AJCC v6 and v7", "Stage II Bladder Cancer AJCC v6 and v7", "Stage III Bladder Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Genistein", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2005-06-24", "completion_date": "2010-08-15", "has_results": true, "last_update_posted_date": "2021-06-10", "last_synced_at": "2026-10-02T12:11:55.169Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Laguna Hills, California • Iowa City, Iowa + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Garden City", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00118040" } ] }